Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending March 01, 2006. The report details a specific corporate action regarding the repurchase of the company's own ordinary shares.
Key Financial Metrics
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The only financial data disclosed relates to the share repurchase transaction:
- Shares Purchased: 1,000,000 ordinary shares of 25 pence each.
- Purchase Price: 1,461.8114 pence per share.
- Total Treasury Shares: 148,154,678 shares held in Treasury following the transaction.
- Shares in Issue: 5,820,019,411 shares (excluding Treasury shares).
Material Changes
The material change reported is the reduction of outstanding shares through a buyback executed on March 1, 2006, pursuant to shareholder authority granted at the Annual General Meeting on May 25, 2005. The company intends to hold the repurchased shares in Treasury.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or discussion of contingencies. It explicitly states that the announcement does not constitute an offer or solicitation to purchase or subscribe for securities in any jurisdiction.
Investor Verification Points
- Verify the total number of shares held in Treasury (148,154,678) against subsequent filings to track ongoing buyback activity.
- Confirm the total number of shares in issue (5,820,019,411) to assess dilution or concentration effects.
- Note that this filing is a notification of a specific transaction and does not contain comprehensive financial results for the period.